Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials.
Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
Company Details
- Employees
- 268
- Address
- 12790 El Camino Real, San Diego,california,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ventyxbio.com/
- Keywords
- Coordinator jobs.
- HQ
- San Diego, California
Ventyx Biosciences Questions
Ventyx Biosciences's website is https://ventyxbio.com/
Ventyx Biosciences's LinkedIn profile is https://www.linkedin.com/company/ventyx-biosciences
Ventyx Biosciences has
268 employees.
View email and phone details for 268
employees at Ventyx Biosciences.
Ventyx Biosciences's industry is
Biotechnology Research
Ventyx Biosciences's top competitors are
Avidity Biosciences, Inc.,
Adarx Pharmaceuticals Inc.,
Cue Biopharma,
Longbio Pharma,
Janux Therapeutics,
Kailera Therapeutics,
Mirador Therapeutics,
Neurocrine Biosciences,
Lift Biosciences,
Crinetics Pharmaceuticals.
Ventyx Biosciences's categories are Biotechnology Research
